Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

Abstract

Tocilizumab was efficacious in severe, persistent systemic JIA. Adverse events were common and included infection, neutropenia, and increased aminotransferase levels.

Keywords

• Juvenile Idiopathic Arthritis
• Infection
• Neutropenia